EXEL:NASDAQ
Exelixis Inc
$59.01
arrow_downward
-0.20%(-0.12) 1D
$59.01
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 4, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$58.50
High
$59.26
Low
$58.46
Mkt. cap
14.62B
Avg. vol.
2.53M
Volume
1.58M
P/E ratio
18.53
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
Open
$58.50
High
$59.26
Low
$58.46
Mkt. cap
14.62B
Avg. vol.
2.53M
Volume
1.58M
P/E ratio
18.53
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
News stories
From web sources and news partners
Investor's Business Daily
·
6 hours ago
IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out
Yahoo Finance
·
7 hours ago
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Zacks
·
1 day ago
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com